Paritaprevir

Paritaprevir is a direct acting antiviral medication used as part of combination therapy to treat chronic Hepatitis C, an infectious liver disease caused by infection with Hepatitis C Virus (HCV). Its therapeutic use is listed as antivirals. The directory classifies it as a discontinued API with a synthetic source/manufacturing origin. Other names for this substance include Veruprevir, (2R, 6S, 12Z, 13aS, 14aR, 16aS)-N-(Cyclopropylsulfonyl)-6-{[(5-methylpyrazin-2-yl)carbonyl]amino}-5, 16-dioxo-2-(phenanthridin-6-yloxy)-1, 2, 3, 6, 7, 8, 9, 10, 11, 13a, 14, 15, 16, 16a-tetradecahydrocyclopropa[E]pyrrolo[1, 2-a][1 and 4]diazacyclopentadecine-14a(5H)-carboxamide. It is listed as a controlled drug substance. Its PubChem CID is 45110509.

CAS No 1216941-48-8
Molecular Formula C40H43N7O7S
Molecular Weight 765.9 g/mol
Synonyms (1S,4R,6S,7Z,14S,18R)-N-cyclopropylsulfonyl-14-[(5-methylpyrazine-2-carbonyl)amino]-2,15-dioxo-18-phenanthridin-6-yloxy-3,16-diazatricyclo[14.3.0.04,6]nonadec-7-ene-4-carboxamide

Frequently Asked Questions